BiVictriX Therapeutics plc – Intention to float on AIM

August 02nd, 2021

BiVictriX Therapeutics plc, the developer of targeted cancer therapies based on its novel Bi-Cygni® approach, announces its intention to apply for admission to trading on AIM a market operated by the London Stock Exchange plc.

View PDF Announcement HERE

View Admission Document HERE